SMS Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from SMS Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every ₹100 of sales, ₹46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier. More money tied up than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹86Over the last 3 years, every ₹100 of reported profit came with ₹86 of operating cash.
Lower than 67% of Healthcare companies in India.
Self-Funding Ratio
0.6×Over the last 3 years its own operating cash paid for 62% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 77% of Healthcare companies in India.
Cash Locked Ratio
₹46For every ₹100 of sales, ₹46 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹48 tied up three years earlier.
More money tied up than 86% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹30Sales grew 70% in 3 years; of every extra ₹100 of sales, ₹30 became extra profit.
Higher than 77% of Healthcare companies in India.
Asset Productivity Ratio
+70% / +55%In 3 years sales changed by +70% while total assets changed by +55%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Lower than 78% of Healthcare companies in India.
Cash Cushion Ratio
−8%Debt, after subtracting cash, equals 8% of its market value (net debt).
Lower than 73% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 73% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 73% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
SMS Pharmaceuticals Limited owes ₹0.42 for every ₹1 it owns. Net profit rose 48% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
38.1Investors pay ₹38.1 for every ₹1 of SMS Pharmaceuticals Limited's yearly profit, higher than 53% of Healthcare companies in India.
P/B ratio
5.11The share price is 5.11 times SMS Pharmaceuticals Limited's book value per share, higher than 57% of Healthcare companies in India.
Market cap
₹4,014 CrThe total market value of all of SMS Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 55% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹786 CrWhat SMS Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹83.91Net worth divided by the number of shares. The share price of ₹428.65 is 5.1 times this, which is the P/B above.
Return on equity (ROE)
13.4%SMS Pharmaceuticals Limited earned 13.4% on its shareholders' money over the last year, higher than 54% of Healthcare companies in India.
Owes vs Owns
0.42×SMS Pharmaceuticals Limited owes ₹0.42 for every ₹1 it owns (low), higher than 65% of Healthcare companies in India.
Dividend yield
0.09%SMS Pharmaceuticals Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit growth
+48%Net profit rose 48% in the year to Mar 2026.
Profit margin
11.5%SMS Pharmaceuticals Limited keeps ₹12 of every ₹100 of revenue as net profit.
Cash quality
0.6×Cash from SMS Pharmaceuticals Limited's business was 0.6× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
6.0×SMS Pharmaceuticals Limited's operating profit covered its interest costs 6.0 times in the year to Mar 2026.
Cash vs debt
Net debtSMS Pharmaceuticals Limited had ₹319 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is SMS Pharmaceuticals Limited's P/E ratio?
Investors pay ₹38.1 for every ₹1 of SMS Pharmaceuticals Limited's yearly profit, higher than 53% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For SMS Pharmaceuticals Limited: ₹4,014 Cr ÷ ₹786 Cr (31 Mar 2026) = 5.1.
What is SMS Pharmaceuticals Limited's return on equity?
SMS Pharmaceuticals Limited earned 13.4% on its shareholders' money over the last year, higher than 54% of Healthcare companies in India.
How much does SMS Pharmaceuticals Limited owe compared with what it owns?
SMS Pharmaceuticals Limited owes ₹0.42 for every ₹1 it owns (low), higher than 65% of Healthcare companies in India.
Does SMS Pharmaceuticals Limited pay a dividend?
Yes. SMS Pharmaceuticals Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Is SMS Pharmaceuticals Limited's revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.